SEARCH:   Advanced

Blood, 15 June 2007, Vol. 109, No. 12, pp. 5473-5476. Prepublished online as a Blood First Edition Paper on March 9, 2007; DOI 10.1182/blood-2006-05-021071. This Article Full Text (PDF) Supplemental Appendix, Methods, Tables, and Figures All Versions of this Article: blood-2006-05-021071v1 109/12/5473    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Gregorj, C. Articles by Tafuri, A. Search for Related Content PubMed PubMed Citation Articles by Gregorj, C. Articles by Tafuri, A. Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted May 9, 2006 Accepted February 27, 2007 ERK1/2 phosphorylation is an independent predictor of complete remission in newly diagnosed adult acute lymphoblastic leukemia Chiara Gregorj, Maria R Ricciardi, Maria T Petrucci, Maria C Scerpa, Fabiana De Cave, Paola Fazi, Marco Vignetti, Antonella Vitale, Marco Mancini, Giuseppe Cimino, Salvatore Palmieri, Francesco Di Raimondo, Giorgina Specchia, Francesco Fabbiano, Nicola Cantore, Federico Mosna, Andrea Camera, Mario Luppi, Luciana Annino, Eustachio Miraglia, Giuseppe Fioritoni, Francesca Ronco, Giovanna Meloni, Franco Mandelli, Michael Andreeff, Michele Milella, Robin Foa, and Agostino Tafuri* Division of Hematology, Dept of Cellular Biotechnologies and Hematology, University "La Sapienza", Rome, Italy GIMEMA Foundation, Data Center, Rome, Italy Divisione di Ematologia, Azienda Ospedaliera di Rilievo Nazionale "A. Cardarelli", Napoli, Italy Cattedra di Ematologia, Ospedale "Ferrarotto", Universita degli Studi di Catania, Italy Unita Operative Ematologia 1, Universita degli Studi di Bari, Italy Divisione di Ematologia, Azienda Ospedaliera "V. Cervello" di Palermo, Italy Ematologia, Azienda Ospedaliera "S.G. Moscati" di Avellino, Italy Divisione di Ematologia, Policlinico G.B. Rossi, Universita degli Studi di Verona, Italy Ematologia, Universita degli Studi Federico II di Napoli, Italy Dipartimento di Oncologia ed Ematologia, Universita degli Studi di Modena e Reggio Emilia, Italy Unita Operativa di Ematologia, Complesso Ospedaliero S. Giovanni Addolorata di Roma, Italy Divisione di Ematologia, A.S.L. Napoli 1 Ospedale San Giovanni Bosco di Napoli, Italy Unita Operativa di Ematologia Clinica, Azienda USL di Pescara, Italy Dipartimento Emato-Oncologia, Azienda Ospedaliera "Bianchi-Melacrino-Morelli" di Reggio Calabria, Italy Section of Molecular Hematology & Therapy, University of Texas M.D.Anderson Cancer Center, Houston, TX, United States Division of Medical Oncology A, Regina Elena Cancer Institute, Rome, Italy * Corresponding author; email: agotaf{at}bce.uniroma1.it. Extracellular signal-regulated kinase-1/2 (ERK1/2) is frequently found constitutively activated (p-ERK1/2) in hematopoietic diseases, suggesting a role in leukemogenesis. The aim of this study was to assess the expression and clinical role of p-ERK1/2 in adult acute lymphoblastic leukemia (ALL). In 131 primary samples from adult de novo ALL patients enrolled in the GIMEMA LAL2000 protocol and evaluated by flow cytometry, constitutive ERK1/2 activation was found in 34.5% of cases, resulting significantly associated with higher WBC values (P=0.013). In a multivariate analysis, p-ERK1/2 expression was an independent predictor of complete remission achievement (P=0.027). Effective approaches toward MEK inhibition need to be explored in order to evaluate whether this may represent a new therapeutic strategy for adult ALL patients. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

	Copyright © 2007 by American Society of Hematology         Online ISSN: 1528-0020